BioProtect Balloon for Prostate Cancer

Prostate cancer can be treated effectively nowadays using  high dose radiation therapy. Radiation therapy uses high-energy rays focused on the prostate gland to kill cancer cells. Treatment is planned using advanced software to ensure that an optimal dose is administered to the tumor while minimizing exposure of healthy surrounding tissues. However, due to prostate movements there is a chance that nearby sensitive organs, such as the rectum, will be exposed to damaging radiation – resulting in toxicity.

Rectal toxicity can cause pain, bowel problems, bleeding and chronic internal wounds that may impair the quality of life.

The BioProtect Balloon Implant separates the prostate from the rectum, shifting the rectum away from the high radiation zone, protecting it from the harmful effects of radiation and eliminating rectal toxicity. The balloon is made of special polymers that dissolve in the body – it stays in place during the treatment and after 6 months it completely disappears.

The BioProtect Balloon comes rolled on a special device and is inserted through a small incision in the skin in a simple ambulatory procedure that takes 10-15 minutes under local or general anesthesia. Patients do not feel the balloon and do not report of any irritation or discomfort

balloon31The BioProtect Balloon Implant has been successfully implanted in hundreds of patients across Europe. The product
passed all necessary clinical tests and scrutiny by the CE Mark and is now commercially available in Europe.

For more information please contact your local BioProtect agent.

You may find additional information on prostate cancer and the BioProtect Balloon Implant here:

[i] National Cancer Institute. Website: http://www.cancer.gov/cancertopics/types/prostate

[ii] Breslow, N; Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H. (November 15 1977). “Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France”. Int J Cancer 20 (5): 680–8. doi:10.1002/ijc.2910200506PMID 924691.